The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Clinical Trial of Ixekizumab for Psoriatic Arthritis Shows Positive Results

Clinical Trial of Ixekizumab for Psoriatic Arthritis Shows Positive Results

October 12, 2016 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270A recent Phase 3 clinical trial found that an increased number of interleukin (IL)-17A-producing cells are present in the peripheral blood, synovial tissue and fluid, and skin plaques of patients with psoriatic arthritis (PsA).1 The IL-17A cytokine increases joint inflammation and damage by triggering activation and movement of immune cells (e.g., proinflammatory cytokines, chemokines)—thus, acting as a chemo-attractant to neutrophils and monocytes and stimulating release of matrix metalloproteases and receptor activator of nuclear factor kappa-B ligand—helping destroy cartilage and bone. Therefore, inhibiting IL-17A-producing cells helps treat PsA.

You Might Also Like
  • Ixekizumab Eases Psoriatic Arthritis when TNF Inhibitor Fails
  • Plaque Psoriasis: Secukinumab Beats Ustekinumab in a Head-to Head Clinical Trial & Ixekizumab Helps Improve Productivity
  • Biologic DMARDs Prove Effective for Psoriatic Arthritis & Combination DMARDs Show Promise for RA
Also By This Author
  • Drugs Studied for Use in Rheumatoid Arthritis, Weight Loss

The study assessed the safety and efficacy of ixekizumab, an anti-IL-17A monoclonal antibody. This randomized, 24-week, double-blind, placebo- and active-controlled trial was conducted in patients with active PsA. It compared two ixekizumab regimens and an active reference arm of adalimumab with placebo. Biologic-naive PsA patients were randomized to receive subcutaneous injections of one of the following: 40 mg adalimumab once every two weeks (n=101), 80 mg ixekizumab once every two weeks (n=103), 80 mg ixekizumab once every four weeks (n=107) or placebo (n=106). Patients were allowed to remain on stable doses of conventional disease-modifying antirheumatic drugs (DMARDs), oral corticosteroids, opiates and/or non-steroidal anti-inflammatory drugs/cyclo-oxygenase-2 inhibitors. The ixekizumab treatment regimens included a 160 mg initial dose.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The primary study objective was to assess the superiority of the ixekizumab regimens compared with placebo using the American College of Rheumatology 20 (ACR20) response at Week 24. Secondary endpoints included the proportion of patients achieving ACR50 or ACR70 responses; the proportion of patients achieving a 75%, 90% or 100% improvement of the Psoriasis Area and Severity Index score (PASI 75, PASI 90 and PASI 100); the percentage of psoriasis-affected body surface area; and the change from baseline in the Health Assessment Questionnaire-Disability Index.

Significantly more ixekizumab-treated patients achieved an ACR20 response compared with placebo-treated patients (every two weeks, 62%; every four weeks, 58%; placebo, 30%). Compared with placebo-treated patients, both groups of ixekizumab-treated patients had significantly improved disease activity and functional ability at Weeks 12 and 24, as well as significantly less structural damage progression at Week 24 (P≤0.01). Also, plaque psoriasis clearance was greater in ixekizumab-treated patients compared with placebo-treated patients (P≤0.001). Adalimumab-treated patients showed significant improvements compared with placebo-treated patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

PASI 100 was reached at Week 24 in 43% of patients treated with ixekizumab every four weeks, 53% of those treated with ixekizumab every two weeks and 24% of those in the adalimumab-treated group. More ixekizumab-treated patients and adalimumab-treated patients compared with placebo-treated patients had treatment emergent adverse events (66%, 64%, 47%, respectively; P<0.05). Most reactions were mild or moderate and included injection-site reactions, injection-site erythema and nasopharyngitis.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: adalimumab-atto, IL-17, ixekizumab, Psoriatic Arthritis

You Might Also Like:
  • Ixekizumab Eases Psoriatic Arthritis when TNF Inhibitor Fails
  • Plaque Psoriasis: Secukinumab Beats Ustekinumab in a Head-to Head Clinical Trial & Ixekizumab Helps Improve Productivity
  • Biologic DMARDs Prove Effective for Psoriatic Arthritis & Combination DMARDs Show Promise for RA
  • Results of SPIRIT: A Head-to-Head Trial of Ixekizumab vs. Adalimumab in Active PsA

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.